Karen McCoy

Also affiliated with The Ohio State University

MedicineHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials”.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00434-9

N/A

3.9DataRank · unranked

127 citations

Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki +91 more

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9

N/A

1.9DataRank · unranked

95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5

N/A

1.5DataRank · unranked

67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00407-7

N/A

1.4DataRank · unranked

50 citations

Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, L. Thia, Philip Robinson +44 more

Cystic Fibrosis Macrophage Function and Clinical Outcomes After Elexacaftor/Tezacaftor/Ivacaftor Initiation

(2021)10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1172

N/A

0DataRank · unranked

0 citations

S. Zhang, Chandra L. Shrestha, B Wisniewski, Nevian Brown, Hanh Thi Pham +2 more

Impact of elexacaftor–tezacaftor–ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis

Pediatric Pulmonology(2022)10.1002/ppul.26261

N/A

0DataRank · unranked

91 citations

Rodney D. Britt, Nancy A. Ryan‐Wenger, Aiman Khan, Brandon W. Lewis, Courtney Gushue +5 more

Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal(2022)10.1183/13993003.02861-2021

N/A

0DataRank · unranked

54 citations

Chandra L. Shrestha, Frank Robledo‐Avila, Devi Jaganathan, B Wisniewski, Nevian Brown +9 more

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.008

N/A

0DataRank · unranked

144 citations

Jonathan B. Zuckerman, Daniel Dorgan, Jorge Lascano, Karen McCoy, Manu Jain +15 more

Airway transcriptome networks identify susceptibility to frequent asthma exacerbations in children

Journal of Allergy and Clinical Immunology(2023)10.1016/j.jaci.2023.02.031

N/A

0DataRank · unranked

17 citations

Kimberly A. Dill‐McFarland, Arjun Kothari, R. Max Segnitz, Jeff Burkle, Brittany Grashel +13 more

Innate immune responses are increased in children with acute asthma exacerbation

Pediatric Allergy and Immunology(2024)10.1111/pai.14173

N/A

0DataRank · unranked

5 citations

Mariah Eisner, Joshua Walum, Kathryn M. Heyob, Aiman Khan, Brandon Lewis +5 more

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

UNC Libraries(2020)10.17615/4fd2-ak86

N/A

0DataRank · unranked

30 citations

George Retsch‐Bogart, Ronald L. Gibson, Christopher M. Oermann, Alexandra L. Quittner, A. Bruce Montgomery +1 more

CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.08.656500

N/A

0DataRank · unranked

1 citations

Raúl Rascón, A. Montanez-Barragan, Veronica Loyo-Celis, Harpreet Singh, Karen McCoy +3 more

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

UNC Libraries(2020)10.17615/fm1q-nk97

N/A

0DataRank · unranked

31 citations

Michael W. Konstan, Steven M. Rowe, Manfred Ballmann, Laurent Vernillet, Jordan Dunitz +25 more

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

UNC Libraries(2020)10.17615/kj1j-fh94

N/A

0DataRank · unranked

0 citations

Christopher M. Oermann, Ronald L. Gibson, Peter Cooper, Alexandra L. Quittner, Karen McCoy +2 more

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

UNC Libraries(2020)10.17615/6bzt-sb09

N/A

0DataRank · unranked

0 citations

George Retsch‐Bogart, Karen McCoy, A. Bruce Montgomery, Peter Cooper, Christopher M. Oermann +2 more